The MSKCC Center for Translational Cancer Genomic Analysis, a Genome Data Analysis Center type B (GDAC-B), aims to develop novel integrative analysis methods for studying cancer genomic data, thereby enabling the translation of genomic insights into new clinical applications. The planned novel translational genomics analyses are presented in four specific aims organized around four themes: Subtype discovery. Pathway analysis, Therapy nomination, and Software development. These methods will be critical to helping the Cancer Genome Atlas (TCGA) project meet its stated objective of accelerating our understanding of the molecular basis of cancer, and improving our ability to diagnose, treat, and prevent cancer. The analysis work and method development will be closely coordinated with the GDACs working group (GDAC-WG), software tools will be fully integrated with the TCGA analytic pipelines and results of analyses will be made freely available to the scientific community via TCGA internet portals, with well-established plans for caBIG interoperability. The work of this GDAC-B will build on the flow of data from Genome Characterization Centers and Genome Sequencing Centers, as integrated by the GDAC-A data analysis centers. The applicant group of the MSKCC Center for Translational Cancer Genomic Analysis has a strong track record in large scale collaborative cancer genomics within the TCGA pilot phase and other consortia, and benefits from a computational biology program that is uniquely embedded in a comprehensive cancer center with a major focus on basic and translational research.

Public Health Relevance

Over the next five years, The Cancer Genome Atlas (TCGA) will generate the most detailed information ever obtained on the abnormalities present in many different types of cancer. To make sense of this unprecedented amount of information, the MSKCC Center for Translational Cancer Genomic Analysis will develop new ways of analyzing this information, to enable and hasten the translation of these novel insights into new clinical advances in the diagnosis and treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-U (O1))
Program Officer
Yang, Liming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Gao, Jianjiong; Ciriello, Giovanni; Sander, Chris et al. (2014) Collection, integration and analysis of cancer genomic profiles: from data to insight. Curr Opin Genet Dev 24:92-8
Weinhold, Nils; Jacobsen, Anders; Schultz, Nikolaus et al. (2014) Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46:1160-5
Aksoy, Bülent Arman; Demir, Emek; Babur, Özgün et al. (2014) Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics 30:2051-9
Shinbrot, Eve; Henninger, Erin E; Weinhold, Nils et al. (2014) Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 24:1740-50
Hoadley, Katherine A; Yau, Christina; Wolf, Denise M et al. (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929-44
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-22
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-9
Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-50
Hakimi, A Ari; Furberg, Helena; Zabor, Emily C et al. (2013) An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 105:1862-70
Lianoglou, Steve; Garg, Vidur; Yang, Julie L et al. (2013) Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. Genes Dev 27:2380-96

Showing the most recent 10 out of 33 publications